Efficacy and Safety of ALT-801 in the Treatment of Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

391

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions
Obesity/Overweight
Interventions
DRUG

ALT-801

Injected subcutaneously (SC)

OTHER

Placebo

Injected subcutaneously (SC)

Trial Locations (31)

10001

Altimmune CTM, New York

10065

Cornell University, Joan and Sanford Weill Medical College, New York

19092

Altimmune CTM, Philadelphia

31411

Altimmune CTM, Savannah

32123

Altimmune CTM, Port Orange

32201

Altimmune CTM, Jacksonville

33319

Altimmune CTM, Sunrise

33427

Altimmune CTM, Boca Raton

33755

Altimmune CTM, Clearwater

33900

Altimmune CTM, Fort Myers

35020

Altimmune CTM, Birmingham

37901

Altimmune CTM, Knoxville

40202

Altimmune CTM, Louisville

45201

Altimmune CTM, Cincinnati

46201

Altimmune CTM, Indianapolis

46260

Midwest Institute for Clinical Research, Indianapolis

59701

Altimmune CTM, Butte

60201

Altimmune CTM, Evanston

64101

Altimmune CTM, Kansas City

70119

Altimmune CTM, New Orleans

70801

Altimmune CTM, Baton Rouge

77401

Altimmune CTM, Bellaire

78201

Altimmune CTM, San Antonio

78701

Altimmune CTM, Austin

84770

Altimmune CTM, St. George

85201

Altimmune CTM, Mesa

90001

Altimmune CTM, Los Angeles

90057

National Research Institute, Los Angeles

91763

Altimmune CTM, Montclair

93101

Altimmune CTM, Santa Barbara

08009

Altimmune CTM, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY